MannKind Corporation Company Profile & Data: stocks, market cap, financials, digital and more

                        
Company
MannKind CorporationHeadquarters: Westlake Village, 
                        CA, United States
                    
Founded: 1991
Employees: 348
CEO: Dr. Michael E. Castagna

                                    NASDAQ: MNKD
                                
                                            +0.10%
                                            
Market Cap$1.66 Billion

                        USD as of Jan. 1, 2025
                    
                            Market Cap History

MannKind Corporation Categories

United States Healthcare Biotechnology
United States Healthcare United States Biotechnology

MannKind Corporation market capitalization over time

Evolution of MannKind Corporation market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of MannKind Corporation

Top Competitors by Market Capitalization

Industry: Biotechnology

Company	Market Cap (USD)
Novo Nordisk	$622.07 B
Vertex Pharmaceuticals Incorporated	$113.24 B
CSL Limited	$95.75 B
Regeneron Pharmaceuticals, Inc.	$76.33 B
Marinomed Biotech AG	$56.13 B

Sector:

Company	Market Cap (USD)
Lilly	$689.42 B
Novo Nordisk	$622.07 B
UnitedHealth Group	$487.54 B
Johnson & Johnson	$353.05 B
AbbVie	$301.60 B

Detailed Description

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.

Tweets by MannKind Corporation

Top 1-year algo backtest: +327.04%

$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Financials

Last Financial Reports Date	Sept. 30, 2024
Revenue TTM	$267.2 M
EBITDA	$76.5 M
Gross Profit TTM	$192.1 M
Profit Margin	8.07%
Operating Margin	21.71%
Quarterly Revenue Growth	36.70%